Project Grant R44CA247503

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $624,001.00 to New York University School of Medicine to develop a novel class of drug candidates called multivalent peptoid conjugates (MPCs) that can effectively antagonize the androgen receptor (AR) in prostate cancer. The goal is to create MPC-based therapeutics that can stop the growth of prostate cancer cells, including those resistant to standard anti-androgen agents like...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC for the development and validation of CTT2274, a novel PSMA-targeted small molecule prodrug for the treatment of advanced prostate cancer. The funding will enable the company to: (1) perform process development and optimization of the CTT2274 synthetic procedures, (2) assess the pharmacokinetics of CTT2274, and (3) determine the minimum...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,881 to Duke University for the development and testing of novel immunotherapies using optimized tumor cell-penetrating antibodies. The primary objective is to translate these innovative antibody-based therapies into the clinic to effectively combat aggressive, mutation-driven human cancers. The key products or services to be delivered under this 5-year award include:...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $720,416 to the Sloan-Kettering Institute for Cancer Research to develop a novel theranostic chimeric antigen receptor (CAR) T-cell therapy for neuroendocrine prostate cancer (NEPC). The key objectives are to evaluate the therapeutic efficacy of DLL3-specific CAR-T cells, create DLL3/PSMA bi-specific CAR-T cells, and validate the ability to track the CAR-T cells and...

This federal Project Grant award for $680,453, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to investigate the use of cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer (mCRPC). The 5-year study will pursue three specific aims: 1) determine if baseline cell-free tumor DNA (ctDNA) fragmentomics scores are prognostic...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $652,414 to The Washington University in St. Louis to conduct a Phase 1 clinical trial assessing the safety, tolerability, and anti-tumor activity of the novel ACK1 inhibitor drug (R)-9B in patients with castration-resistant prostate cancer (CRPC). The key objectives are to: Evaluate the safety, tolerability, and pharmacokinetics of (R)-9B in CRPC patients. Assess peripheral...

The National Cancer Institute (NCI) awarded a $393,401 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Washington State University (WSU) to develop a PSMA-targeted small-molecule dual drug conjugate (SMDDC) for treating metastatic castration-resistant prostate cancer (mCRPC) and other PSMA-positive malignancies. The project aims to assess the spatio-temporal cargo release of a PSMA-targeted SMDPC and determine the potency enhancement of a SMDDC bearing dual chemotherapeutic payloads...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Nuago Therapeutics Inc. to develop a novel, RNA-interference-based therapeutic to treat prostate cancer. The goal is to develop an sCAG-based therapeutic, delivered via lipopolyplex nanoparticles, that can target and silence genes essential for prostate cancer cell survival. The funded work will evaluate the uptake and silencing activity of this therapeutic in...

The federal Project Grant award R01CA287510, "TARGETING UNDRUGGABLE TRANSCRIPTION FACTOR HOXB13 TO INHIBIT PROSTATE CANCER METASTASIS", is funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $636,289 award to Duke University aims to develop a lipid nanoparticle (LNP) system for delivering the CRISPR/Cas13d system to target the oncogenic transcription factor HOXB13 and inhibit metastasis in castration-resistant prostate cancer....

The National Cancer Institute (NCI) awarded a $553,550 Project Grant (CFDA 93.395 Cancer Treatment Research) to Cedars-Sinai Medical Center for a translational study on a synthetic lethality interaction between CD105 and androgen receptor signaling for castration-resistant prostate cancer patients. The goal is to better understand a novel signaling axis initiated in prostate cancer patients by next-generation androgen receptor signaling inhibitors (ARSIs), which can lead to therapeutic...